Gene-expression assays and personalized cancer care: Tissue-of-origin test for cancer of unknown primary origin

Personalized Medicine

Volumn 8, Issue 4, 2011, Pages 429-436

  Takei, Hidehiro ^a   Monzon, Federico A ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cancer of unknown primary; gene expression assay; immunohistochemistry; microarrays; molecular diagnostics; personalized cancer care; site directed therapy; tissue of origin test

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; THYROGLOBULIN; TUMOR MARKER;

ADVANCED CANCER; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; COLORECTAL CARCINOMA; DIAGNOSTIC IMAGING; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 79960948113     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.37     Document Type: Review

References (37)

1. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 9(6), 596-599 (2008). (Pubitemid 351722584)
2. Greco FA, Hainsworth JD. Cancer of unknown primary site. In:Cancer: Principles and Practice of Oncology (8th Edition). DeVita VTJ, Hellman S, Rosenberg SA (Eds), Lippincott, Philadelphia, PA, USA, 2363-2387 (2008).
3. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann. Oncol. 21(Suppl. 7), vii303-vii307 (2010).
4. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N. Engl. J. Med. 329(4), 257-263 (1993). (Pubitemid 23203818)
5. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systemic literature review. Cancer Treat. Rev. 35(3), 221-227 (2009).
6. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer 43(14), 2026-2036 (2007). (Pubitemid 47380362)
7. Bishop JF, Tracey E, Glass P, Jelfs P, Roder D. Prognosis of sub-types of cancer of unknown primary (CUP) compared with metastatic cancer. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 21010).
8. Greco FA. Evolving understanding and current management of patients with cancer of unknown primary site. Commun. Oncol. 7(4), 183-188 (2010).
9. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP).Crit. Rev. Oncol. Hematol. 69(3), 271-278 (2009).
10. Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin. Oncol. 36(1), 65-74 (2009).
11. Hainsworth JD, Fizaki K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin. Oncol. 36(1), 44-51 (2009).
12. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin. Oncol. 36(1), 38-43 (2009).
13. Oien KA. Pathologic evaluation of unknown primary cancer. Semin. Oncol. 36(1), 8-37 (2009).
14. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl. Immunohistochem. Mol. Morphol. 18(1), 3-8 (2010).
15. Hemminki K, Ji JG, Sundquist J, Shu XC. Familial risks in cancer of unknown primary: tracking the primary sites. J. Clin. Oncol. 29(4), 435-440 (2011).
16. Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 62(21), 5999-6005 (2002). (Pubitemid 35244442)
17. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 61(20), 7388-7393 (2001). (Pubitemid 32995021)
18. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch. Pathol. Lab. Med. 134(2), 216-224 (2010).
19. Ma XJ, Patel R, Wang X et al. Molecular classification of human cancer using a 92-gene real-time quantitative polymerase chain reaction assay. Arch. Pathol. Lab. Med. 130(4), 465-473 (2006).
20. Pillai R, Deeter R, Rigl CT et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J. Mol. Diagn. 13(1), 48-56 (2011).
21. Monzon FA, Lyons-Weiler M, Buturovic LJ et al. Multicenter validation of a 1550-gene expression profile for identification of tumor tissue of origin. J. Clin. Oncol. 27(15), 2503-2508 (2009).
22. Monzon FA, Stancel GA, Alvarez K, Fairley T, Mody D, Coffey D. Performance of a gene expression microarray assay to determine tissue of origin in cytology body fluid specimens. Poster presented at: United States & Canadian Academy of Pathology (USCAP) Annual Meeting, TX, USA 26 February-4 March 4 2011.
23. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848-5856 (2009).
24. Li J, Smyth P, Flavin R et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 7, 36 (2007).
25. Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26(4), 462-469 (2008). (Pubitemid 351501813)
26. Rosenwald S, Gilad S, Benjamin S et al. Validation of micro-RNA based qRT-PCR test for accurate identification of tumor tissue origin. Mod. Pathol. 23(6), 814-823 (2010).
27. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 15(5), 500-506 (2010).
28. Varadhachary GR, Talantov D, Raber MN et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J. Clin. Oncol. 26(27), 4442-4448 (2008).
29. Hainsworth JD, Spigel DR, Rubin MS et al. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, Phase II trial. J. Clin. Oncol. 28(Suppl. 15), (2010) (Abstract 10540).
30. Hornberger JC, Amin M, Varadhachary GR, Henner WD, Nystrom JS. Effect of a gene expression-based tissue of origin test's impact on patient management for difficult-to-diagnose primary cancers. J. Clin. Oncol. 29(Suppl. 4) (2011) (Abstract 459).
31. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol. Cancer. Res. 8(9), 1175-1187 (2010).
32. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin. Oncol. 36(1), 75-80 (2009).
33. Greco FA, Erlander MG. Molecular classification of cancers of unknown primary site. Mol. Diagn. Ther. 13(6), 367-373 (2009).
34. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95(1), 14-18 (2003). (Pubitemid 36124291)
35. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23(29), 7332-7341 (2005). (Pubitemid 46202346)
36. Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin. Cancer Res. 11(10), 3766-3772 (2005). (Pubitemid 40685594)
37. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: true identity by immunohistochemistry. Arch. Pathol. Lab. Med. 132(3), 326-348 (2008). (Pubitemid 351328809)